D
Delix Therapeutics
Applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics
About Delix Therapeutics
Delix Therapeutics is a pioneering startup operating in the healthcare sector, specifically focusing on brain health therapeutics. The company is leveraging a unique class of compounds, known as psychoplastogens or neuroplastogens, to develop innovative treatments for mental health disorders. These treatments are designed to be safe, fast-acting, and long-lasting, addressing a significant need in the market.
The company's business model revolves around the research, development, and commercialization of these novel compounds. Delix Therapeutics operates in the pharmaceutical industry, serving clients who are in need of effective and long-lasting treatments for mental health disorders. This includes individuals suffering from conditions such as depression, anxiety, and other related disorders.
The company generates revenue through the development and sale of these therapeutic treatments. By pushing the boundaries of neuroscience, Delix Therapeutics aims to usher in a new era of brain health, creating a whole new type of medicine that could revolutionize the treatment of mental health disorders.
In terms of market, Delix Therapeutics operates in a sector that is witnessing increasing demand due to the growing awareness and understanding of mental health issues. The company's innovative approach and commitment to developing safe and effective treatments position it well to capitalize on this growing market.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Bedford, United States
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 62.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, Psychedelic Drugs, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Sep 2025 | $0 | — | Universiry of California, Davis | ↗ |
| GRANTOther financing | Jun 2024 | $825K | — | US Department of War | ↗ |
Growth signals
Latest recorded traffic for Delix Therapeutics is 4.2K monthly website visits, down 14.3% over the last three months. Delix Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
OMX Ventures
Presight Capital
US Department of War
Series A17 investors entered at this stage
RA Capital Management
Artis Ventures
Casa Verde Capital
Vertical Venture Partners
Apeiron
re.Mind Capital
Palo Santo Venture Fund
PsyMed Ventures
Ocama Partners- RVR2 Ventures
Dolby Family Ventures
Bail Capital
Noetic Fund
WPSS Investments
Negev Capital- SBSaya Bio
Universiry of California, Davis
Series B and later1 investor entered at this stage
Comerica Bank
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Delix Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Delix Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.